Latest Management of heart failure Stories
-- Phase II, randomized, placebo-controlled study at Glenfield Hospital, University of Leicester (UK) will measure primary efficacy endpoint of change from baseline in left ventricular ejection fraction (LVEF) post-percutaneous coronary intervention (PCI) -- TORONTO, May 2, 2013 /PRNewswire/ -- CellAegis Devices, Inc., announced today the first clinical trial program in the European Union to evaluate the use of the Company's autoRIC(TM) Device for Chronic Remote Ischemic Conditioning...
ZUG, Switzerland, February 11, 2013 /PRNewswire/ -- Cardiorentis has initiated the first-ever acute heart failure (AHF) Phase III trial to be specifically designed to assess the effect of early treatment on cardiovascular mortality. TRUE-AHF (TRial of Ularitide's Efficacy and safety in patients with Acute Heart Failure) aims to show that early treatment with intravenous (IV) ularitide may reduce AHF symptoms in the short-term and cardiovascular mortality in the long-term....
SAN DIEGO, Dec. 11, 2012 /PRNewswire/ -- Celladon Corporation, a biopharmaceutical company focused on the discovery and development of innovative treatments for cardiovascular diseases, announced today that it has dosed the first European patient in its ongoing international Phase 2b clinical trial of MYDICAR, Celladon's first in class therapeutic for the treatment of advanced heart failure (HF). The Phase 2b study titled "Calcium Up-Regulation by Percutaneous Administration of...
A novel study from Karolinska Institutet in Sweden suggests that commonly used drugs to treat heart failure and high blood pressure may have a wider range of application than earlier known, and also can be used against so called HFPEF -- a type of heart failure that until now has been impossible to treat. The study, which is published in the scientific journal JAMA, shows that the mortality rate in a group of HFPEF patients who used these medications decreased. Heart failure affects 3 per...
An analysis of two heart failure therapies finds differing outcomes regarding improvement in survival, according to two studies appearing in the November 28 issue of JAMA. In one study, Adrian F. Hernandez, M.D., M.H.S., of the Duke Clinical Research Institute, Durham, N.C., and colleagues examined the clinical effectiveness of aldosterone antagonist therapy and associations with long-term outcomes of older patients discharged from a hospitalization for heart failure. "Aldosterone...
NATICK, Mass., Nov. 6, 2012 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) and the University of Rochester Medical Center presented positive results from the Multicenter Automatic Defibrillator Implantation Trial-Reduce Inappropriate Therapy (MADIT-RIT) clinical trial that demonstrated improved programming of Boston Scientific dual-chamber implantable cardioverter defibrillator (ICD) or cardiac resynchronization therapy defibrillator (CRT-D) heart devices can reduce...
Heart failure in children often goes unrecognized until it's too late The Canadian Cardiovascular Society is the first in Canada to issue guidelines aimed at helping primary care and emergency physicians, as well as specialists, recognize and manage heart failure in children. The guidelines were released today at the Canadian Cardiovascular Congress. Pediatric heart failure is often fatal and occurs in about 3,000 children annually in North America. Worldwide, the problem is far greater...
SEATTLE, Sept. 9, 2012 /PRNewswire/ -- The Heart Failure Society of America's (HFSA) 16(th) Annual Scientific Meeting convenes Sunday, September 9, 2012 at the Washington State Convention Center in Seattle. This four-day meeting--a forum for heart failure specialists to present research findings and advances in treatment--will address emerging trends in research and new developments in the approach to treating patients with all stages of heart failure. The scientific...
Salt Institute cites new report in the British Medical Journal Alexandria, VA (PRWEB) August 28, 2012 Once again, a respected medical journal has published a paper demonstrating that low salt diets cause more sickness and death than regular salt consumption. In the most recent publication in the British Medical Journal, medical researchers, from the US, Italy, the UK and Canada carried out a systematic review and meta-analysis of randomized trials with heart failure patients. They...
SAN DIEGO, Aug. 29, 2012 /PRNewswire/ -- Celladon Corporation, a biopharmaceutical company focused on the discovery and development of innovative treatments for cardiovascular diseases, announced today that it has dosed the first patient in a Phase 2b clinical trial of MYDICAR, Celladon's first in class therapeutic for the treatment of advanced heart failure (HF). Chronic HF is a leading cause of hospitalization and resulted in direct and indirect costs of $39.2 billion to the U.S....
